This resource may include information that has not been approved by the US Food and Drug Administration. For full prescribing information, including. Fosphenytoin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. Medscape – Epilepsy dosing for Cerebyx (fosphenytoin), frequency-based adverse contraindications, pregnancy & lactation schedules, and cost information. be expressed as phenytoin sodium equivalents (PE) when prescribing; There is.
|Published (Last):||18 September 2013|
|PDF File Size:||13.98 Mb|
|ePub File Size:||18.12 Mb|
|Price:||Free* [*Free Regsitration Required]|
All adverse events were recorded during the trials by the clinical investigators using terminology of their own choosing. Each 10 mL vial contains mg PE. Ezetimibe The metabolism of Fosphenytoin can be decreased when combined with Ezetimibe. Ciglitazone The metabolism of Fosphenytoin can be decreased when combined with Ciglitazone. Ergocalciferol The metabolism of Fosphenytoin can be decreased when combined with Ergocalciferol.
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. Bupropion The metabolism of Fosphenytoin can be decreased when combined with Bupropion. Frovatriptan The risk or severity of adverse effects can fosphenyoin increased when Frovatriptan is combined with Fosphenytoin. Inset shows time course for the entire hour sampling period.
Increased frequencies of major malformations such as orofacial clefts and cardiac defectsand abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities including microcephalyand cognitive deficits, prescribint been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy.
Banoxantrone The metabolism of Fosphenytoin can be decreased when combined with Banoxantrone. The incidences of hepatocellular tumors were increased in female mice at all but the lowest dose tested.
These patients may show early signs of phenytoin toxicity or an increase in the severity of adverse events due to alterations in Pro-Epanutin and phenytoin pharmacokinetics. Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim. Metocurine Iodide The risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Fosphenytoin.
Candesartan The metabolism of Fosphenytoin can be decreased when combined with Candesartan. Phenytoin when given with the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir Calcium channel blockers Nifedipine, nimodipine, nisoldipine, verapamil Other Albendazole decreases active metabolitechlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine.
Esatenolol The metabolism of Esatenolol can be increased when combined with Fosphenytoin. These reactions did not increase in severity with repeated administration.
Fosphenytoin – DrugBank
Prenatal exposure to phenytoin the active metabolite of CEREBYX may increase the risks for congenital malformations and other adverse developmental outcomes [see Use in Specific Populations 8. Moclobemide The metabolism of Fosphenytoin can be decreased when combined with Moclobemide. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.
Clomipramine The informatkon of Clomipramine can be increased when combined with Fosphenytoin.
Cisplatin The metabolism of Fosphenytoin can be decreased when combined with Cisplatin. However, in the event of an allergic or hypersensitivity incormation, rapid substitution of alternative therapy may be necessary. Continuous monitoring of electrocardiogram, blood pressure and respiratory function for the duration of the infusion is essential.
This has the potential to increase the frequency and severity of adverse events. This may or may not be associated with extravasation. Volume mL to draw up. Neuromuscular blocking agents Cisatracurium, pancuronium, rocuronium and vecuronium: Clotrimazole The metabolism of Fosphenytoin can be increased when combined with Clotrimazole.
HIGHLIGHTS OF PRESCRIBING INFORMATION
Alterations in dosing may be necessary in patients with impaired kidney or liver function, elderly patients or those who are gravely ill see section 4. Ixazomib The metabolism of Fosphenytoin can be decreased when combined with Ixazomib. Kaolin Kaolin can cause a decrease in prescribkng absorption of Prescriibng resulting in a reduced serum concentration and potentially a decrease in efficacy.
The location of the discomfort varied with the groin mentioned most frequently as a site of involvement. Magnesium sulfate The therapeutic efficacy of Fosphenytoin can be increased when used in combination with Magnesium sulfate. Ethinylestradiol The metabolism of Fosphenytoin can be decreased when combined with Ethinylestradiol. Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin.
Golimumab The metabolism of Fosphenytoin can be increased when combined with Golimumab. Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D. Fosphenytoin displaces phenytoin from protein binding sites.